Welcome to our dedicated page for Sotera Health Co news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health Co stock.
Sotera Health Company (NASDAQ: SHC) is described as a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Through its Sterigenics, Nordion and Nelson Labs businesses, the company focuses on sterilization, analytical testing and related services that support the safety of medical, pharmaceutical and food products.
The SHC news feed on Stock Titan highlights company announcements that matter to investors and observers of the healthcare services and testing laboratories space. These include quarterly and year-to-date financial results, updates on revenue trends and segment performance for Sterigenics, Nordion and Nelson Labs, as well as information on leverage, credit facilities and other balance sheet items described in press releases and Form 8-K filings.
Users can also follow news about secondary offerings of common stock by selling stockholders, as disclosed in company press releases and related 8-K filings. These items explain when affiliates of investment firms have sold blocks of SHC shares and clarify that Sotera Health did not receive proceeds from those transactions.
Regulatory and legal developments are another important category of news for Sotera Health. Public disclosures describe litigation and settlements related to ethylene oxide emissions at certain Sterigenics facilities, along with broader risk discussions around EO, Co-60 supply, regulatory changes and international operations. Conference participation, earnings release dates and management presentations at healthcare investor events are also covered in the company’s news flow.
By reviewing this news stream, readers can see how Sotera Health communicates its financial performance, capital markets activity, legal developments and strategic positioning in sterilization and lab testing services over time.
Sotera Health (Nasdaq: SHC) appointed Kenneth D. Krause to its Board of Directors, effective March 16, 2026, and he will join the Audit Committee and the Litigation Committee. Krause brings public-company CFO experience from Rollins and MSA Safety and expertise in corporate strategy, capital allocation and governance. Constantine S. Mihas resigned from the Board effective March 16, 2026, due to a reduction in stockholder-designated director slots.
Sotera Health (Nasdaq: SHC) announced a secondary offering of 25 million common shares on March 4, 2026. All shares are being sold by affiliates of Warburg Pincus and GTCR; the company is not selling shares and will not receive proceeds.
Wells Fargo Securities is the underwriter; the company will pay offering expenses under its registration rights agreement. The offering will be made only by prospectus and a registration statement filed February 27, 2024, became effective automatically.
Sotera Health (Nasdaq: SHC) reported 2025 net revenues of $1.164B, up 5.7% (5.2% constant currency); net income of $78M ($0.27/diluted); Adjusted EBITDA of $594M (+8.2%); and Adjusted EPS of $0.86. This marks the 20th consecutive year of revenue growth. Balance sheet: $2.2B total debt, $345M cash, Net Leverage Ratio improved to 3.2x. 2026 outlook: net revenues $1.233–1.251B, Adjusted EBITDA $632–641M, Adjusted EPS $0.93–1.01, and capex $175–225M.
Sotera Health (Nasdaq: SHC) will release fourth-quarter and full-year 2025 financial results before market open on Tuesday, February 24, 2026. Management will host a conference call at 9:00 a.m. Eastern Time the same day and provide a live webcast and replay via the company Investor Relations site.
Presentation materials and periodic updates, including information related to Ethylene Oxide, will be posted on the Sotera Health Investor Relations web pages.
Sotera Health (Nasdaq: SHC) appointed Richard G. Kyle to its Board of Directors effective Feb 5, 2026. Mr. Kyle will join the Leadership Development and Compensation and Nominating and Corporate Governance committees.
He served as President and CEO of Timken from May 2014 to Sept 2024, continues on Timken’s board, and has served on Sonoco’s board since 2015. He holds a B.S. in Mechanical Engineering from Purdue and an M.B.A. from Northwestern.
Sotera Health (Nasdaq: SHC) is presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 to update investors on its business and outlook.
Management said 2025 revenue is expected to surpass $1.16 billion, up at least 5.5% year‑over‑year (or 5.0% on a constant‑currency basis). The company reaffirmed its multi‑year revenue growth streak and announced it will release full‑year results and a 2026 outlook on February 24, 2026. A live webcast and replay of the presentation will be available on the company’s Investor Relations website.
Sotera Health (NASDAQ: SHC) announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 p.m. ET / 10:30 a.m. PT.
Company representatives will also hold investor meetings during the conference. A live webcast and accompanying materials will be posted on the company's Investor Relations website, and a replay will be available within 48 hours and remain archived on the site.
Sotera Health (Nasdaq: SHC) announced a secondary offering of 30,000,000 shares of common stock on November 6, 2025.
All shares are being sold by affiliates of Warburg Pincus and GTCR; the company is not selling shares and will not receive proceeds. Goldman Sachs is the underwriter. The company will pay offering expenses under its registration rights agreement. A registration statement filed with the SEC on February 27, 2024 became effective automatically. The offering is made only by prospectus and is not an offer in jurisdictions where unlawful.
Sotera Health (Nasdaq: SHC) reported Q3 2025 net revenues of $311M, up 9.1% (8.0% constant currency), net income of $48M ($0.17 diluted) and Adjusted EBITDA $164M, up 12.2% (11.2% cc).
Year-to-date net revenues were $860M (+6.2%), Adjusted EBITDA $437M (+10.4%), and Adjusted EPS $0.60. The company raised its 2025 Adjusted EBITDA growth outlook to 6.75%-7.75%, reaffirmed revenue growth of 4.5%-6.0% (cc), and lowered 2025 capex to $125M-$135M. Balance sheet highlights: $2.2B total debt, $299M unrestricted cash, and Net Leverage at 3.3x.
Sotera Health (Nasdaq: SHC) will release third-quarter 2025 financial results for the period ended September 30, 2025 before the market opens on Tuesday, November 4, 2025.
Management will host a conference call at 9:00 a.m. Eastern Daylight Time the same day to discuss results and operating highlights. Participants may dial 1-844-481-2916 (U.S. toll-free) or 1-412-317-0709 from other locations. A live webcast and accompanying materials will be available via the company’s Investor Relations Presentation & Events page, and a replay of the webcast will be posted later on November 4.